Business Wire

Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia

Share

Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based product for acute and chronic wound management, is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”).

After Slovakia, in early 2019 Evopharm will expand the distribution of the product first to Poland, where the registration is currently being completed, and then to Czech Republic.

As confirmed by the results of pre-launch activities, Evopharm is confident that Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, can offer to Slovak Healthcare Professionals (“HCPs”) and caregivers a new treatment option to effectively address the wound healing complexity.

Local KOLs, involved in an Advisory Board, got particularly impressed from the distinctive physico-chemical properties of this product, able to create the ideal microenvironment to sustain the physiological healing process of wounds; clinical evidences have shown Nexodyn® AOS to promote the restart of wound healing, which is considered of great value.

Another benefit of Nexodyn® AOS in interviewed HCPs’ eyes is the local ancillary antimicrobial effect on the wound surface, due to the highly pure and stabilized hypochlorous acid, which can help prevent contamination or contribute to counteract local infections.

“We are very proud about our collaboration with APR and to have the chance to provide Slovak HCPs’ dealing with acute and chronic wounds of such a powerful product. We believe that Nexodyn® AOS, being the first wound cleanser on the Slovak market containing hypochlorous acid, could really make a difference in the treatment of diabetic foot ulcers, lower leg ulcers and pressure ulcers.” commented Martin Hustaty, CEO of Evopharm together with Aneta Manova, CEO of Sanomed.

Sanomed will support the distribution and the promotion of Nexodyn® AOS with a consistent range of activities addressing the HCPs at different levels, from KOLs to hospitals, as well as pharmacists and nurses, like congresses, training courses and e-mailing campaigns, with the purpose of establishing Nexodyn® AOS as the first wound cleanser restarting the physiological healing process of wounds.

”We are very pleased to see Nexodyn® AOS available on Slovak market. This launch comes after previous marketing of the product in Italy, US, Saudi Arabia and UAE, as a result of several partnerships with leading pharmaceutical companies.” said Paolo Galfetti, Chief Executive Officer of APR. “Other markets will follow in the next year confirming Nexodyn® AOS appeal and efficacy among the available wound care solutions”.

About Nexodyn® AcidOxidizing Solution (AOS)

Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.

A wide array of clinical experiences and studies demonstrated Nexodyn® to be a unique Wound healing Restarter by creating the ideal microenvironment to sustain the physiological healing process. Restarting wound healing, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.

Developed based on APR’s proprietary and patented technology Tehclo®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).

Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, and vascular ulcers), post-surgical wounds, burns and other lesions.

As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining the restart of wound healing to the benefit of patients and HCPs who can be confident of the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable safety and tolerability profile and the clinical experiences performed confirm its high relief sensation and comfort at application as well as wound-associated pain reduction.

For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/

About APR Applied Pharma Research s.a.

APR is a Swiss independent pharma company focused on development and commercialization of innovative, science-driven products designed to address unmet needs in niche or rare therapeutic areas on a global basis.

APR combines drug development expertise with proprietary drug delivery technologies to deliver to patients suffering from rare diseases with solutions meaningfully improving their life and empowering caregivers with better ways to manage such rare diseases.

APR has a balanced portfolio of revenue generating products marketed in all major markets, combined with a compelling pipeline of innovative products at different stages of development, specifically in the treatment of rare recessive metabolic disorders, rare dermatological and ocular diseases.

APR’s products are commercialized by APR directly through its own sale and marketing teams in selected countries of Europe as well as through a solid global network of commercial partners.

About Evopharm and/or Sanomed

Since 2010 Evopharm brings a high quality, safe and affordable medicines to the market. Our mission is to provide effective solutions for our patients and help them to live a full and happy life. Our commitment to deliver a high quality and professional service is characterized by the status of a rapidly evolving institution. Complex care management in the field of medicines is realized in Central and Eastern Europe and in selected Asian countries. We naturally pay an attention to the ethical, social and environmental dimensions in our every action and decision.

SANOMED is a dinamically-evolving pharmaceutical company operating in Central and Eastern Europe, contributing a large medicine portfólio to the market since 2011. We provide our business partners with a complex package of services from introductory works, registration, launching of the product to its selling and gaining the expected market share. Our effective and safe medicine from many therapeutic fields returns hopes of a full life to people. We strive to improve patient´s health and quality of life and to be a reliable partner to our clients and associates working in healthcare and pharmaceutical industries.

„We´re doing our best to be beneficial to patients and our healthcare partners alike”.

Contact information

APR Applied Pharma Research s.a.:
Elisabetta Bianchi, Corporate Communication Manager
T +41 91 6957020 or e-mail to: elisabetta.bianchi@apr.ch
or
SANOMED s.r.o.
Silvia Matliakova, Product Manager
e-mail to: silvia.matliakova@sanomed.sk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI Schedules Investor Conference Call to Review Second Quarter 2019 Results16.7.2019 17:49:00 EESTPress release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today it will release its results for second quarter 2019 on Thursday, August 1, 2019. MSCI's senior management will review the second quarter 2019 results on Thursday, August 1, 2019 at 11:00 AM Eastern Time. To listen to the live event, visit the events and presentations section of MSCI's Investor Relations homepage, http://ir.msci.com/events.cfm, or dial 1-877-376-9931 conference ID: 7743929 within the United States. International callers dial 1-720-405-2251 conference ID: 7743929. The earnings release and related investor presentation used during the conference call will be made available on MSCI's Investor Relations homepage. An audio recording of the conference call will be available on our Investor Relations website, http://ir.msci.com/events.cfm, beginning approximately two hours after the conclusion of the live event. Through August 4, 2019,

Keio Plaza Hotel Tokyo Offers “Tea Ceremony Experience and Luxurious Accommodations for Families” Package16.7.2019 17:05:00 EESTPress release

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will begin offering a special summer accommodation package entitled “Tea Ceremony Experience and Luxurious Accommodations for Families” from July 20 to September 1, 2019. This accommodation package has been specially designed to keep families with children entertained by providing the unique cultural experience of a Japanese tea ceremony as fond memories of their summer vacation at our Hotel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005325/en/ With the accommodation package, guests with children could experience unique cultural Japanese tea ceremony to learn how to make a green tea and its history. (Photo: Business Wire) The rooms offered in this accommodation package are the very popular “Two Queen Beds Rooms” located on the “Premier Grand” club floors with use of the Club Lounge included. The rooms are

Andersen Global Enters Senegal, Expands Presence in Africa16.7.2019 16:30:00 EESTPress release

Andersen Global is proud to announce a collaboration agreement with Cabex, one of the oldest legal and tax consulting firms in Senegal. Senegal thus becomes the thirteenth African country where Andersen Global has a member or collaborating firm offering legal services. Located in Dakar, Cabex has been offering services to local and foreign clients from the public and para-public sectors on matters relating to national and international issues for nearly thirty years. “Collaborating with Andersen Global shall expand our international scope and our transborder capabilities while giving us additional opportunities to expand into new markets,” Papa Alassane Ndir, Partner & General Manager at Cabex, said. “Henceforth, we are going to collaborate with many colleagues and experts from around the world and will be in a position to provide our clients more in-depth expertise.” Cherif Diaite, Partner & Technical Manager at Cabex, indicated that, “Owing to the challenge at an international level,

Mercatus Opens UK Office; Hires Chris Webb to Lead European Operations16.7.2019 16:00:00 EESTPress release

Mercatus, a leading asset and investment management platform for alternative investors and asset managers, today announced the opening of its European Headquarters in London, UK and the addition of Chris Webb as Senior Director leading the office in London. Chris was formerly a Global Director of Strategic Business Growth at FIS, with a deep focus on, and expertise in, alternative investments. “As Alternative fund managers and investors across Europe continue to embrace technology – and data – as a competitive weapon to drive future accelerated growth, we’re putting our resources in some of the largest markets. Our London office will be a critical hub for our workings in the UK, expanding upon our other offices in Silicon Valley, New York, Austin, Rome and Pune, India,” said Haresh Patel CEO of Mercatus. “We will continue to expand our local presence across Europe and Asia as our customers have deal and asset management teams in 118 countries with $540B AUM operating within the Mercatu

LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula16.7.2019 16:00:00 EESTPress release

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received CE Mark earlier this year and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery procedures requiring femoral artery cannulation. In a clinical study, Bi-Flow was easily inserted and removed without complications and was proven to provide simultaneous systemic and distal perfusion of the limb in a safe and reproducible way.1 Leg ischemia is caused by compromised blood flow to a lower limb and can affect up to 11% of patients undergoing complex cardiac surgery procedures.2 Consequences can include higher mortality, higher morbidity and longer hospital stays.3 The first procedure in Europe using a Bi-Flow cannula was performed by Patrick Perier M.D., FACS, at the Cardiovascular Center of Bad Neustadt, Germany. “I truly bel

Moody’s to Sell Moody’s Analytics Knowledge Services Business16.7.2019 15:31:00 EESTPress release

Moody’s Corporation (NYSE:MCO) announced today that it has agreed to sell its Moody’s Analytics’ Knowledge Services (MAKS) business to Equistone Partners Europe Limited (Equistone), a European private equity firm. MAKS is a leader in knowledge process outsourcing services, providing high-value research and analytical support to organizations worldwide. Through delivery centers in India, Costa Rica, Sri Lanka and China, the business serves over 250 banks, asset managers and consulting firms with more than 2,500 subject matter experts working as an extension of its clients’ teams. “We are confident that Equistone will be a strong partner for the MAKS business and its customers,” said Mark Almeida, President of Moody’s Analytics. “Equistone provides a platform to support the growth of the business and its continued evolution as a technology-enabled provider of high-quality, cost effective services to global enterprises.” The transaction is expected to close later this year, subject to cus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom